Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma
NCT01778088
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Conditions
Glioma
Interventions
DRUG:
I-131-CLR1404 Injection
Sponsor
Cellectar Biosciences, Inc.